CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.19 and traded as high as $5.79. CASI Pharmaceuticals shares last traded at $5.48, with a volume of 21,567 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of CASI Pharmaceuticals in a research report on Saturday, August 3rd. They set a "hold" rating on the stock.
Read Our Latest Stock Report on CASI Pharmaceuticals
CASI Pharmaceuticals Trading Down 2.5 %
The company has a current ratio of 3.88, a quick ratio of 2.36 and a debt-to-equity ratio of 2.05. The stock has a 50-day simple moving average of $6.07 and a 200 day simple moving average of $5.19.
CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) last issued its quarterly earnings data on Friday, August 16th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.11. The firm had revenue of $3.98 million for the quarter, compared to analysts' expectations of $4.43 million. CASI Pharmaceuticals had a negative net margin of 118.81% and a negative return on equity of 126.20%.
Institutional Investors Weigh In On CASI Pharmaceuticals
A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Free Report) by 10.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,800 shares of the biotechnology company's stock after purchasing an additional 4,000 shares during the period. Renaissance Technologies LLC owned 0.30% of CASI Pharmaceuticals worth $224,000 at the end of the most recent quarter. 22.23% of the stock is owned by institutional investors.
About CASI Pharmaceuticals
(
Get Free Report)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Featured Articles
Before you consider CASI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CASI Pharmaceuticals wasn't on the list.
While CASI Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
